NVNO enVVeno Medical Corp

Nasdaq envveno.com


$ 0.76 $ 0.00 (0 %)    

Friday, 17-Oct-2025 08:53:23 EDT
QQQ $ 598.94 $ 1.02 (0.16 %)
DIA $ 460.55 $ 1.25 (0.27 %)
SPY $ 660.50 $ 1.02 (0.15 %)
TLT $ 91.14 $ -0.11 (-0.12 %)
GLD $ 394.70 $ -2.42 (-0.61 %)
$ 0.787
$ 0.80
$ 0.76 x 100
$ 0.79 x 100
-- - --
$ 0.67 - $ 5.62
223,791
na
15.15M
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-28-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 10-25-2023 09-30-2023 10-Q
9 07-31-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 10-27-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-17-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 06-08-2020 03-31-2020 10-Q
23 03-18-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-05-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 envveno-medical-to-file-supervisory-appeal-after-fda-rejects-venovalve-premarket-approval-application

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

 envveno-medical-announces-fda-not-approvable-decision-on-venovalve-pma-submission

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

 envveno-medical-corporation-releases-preliminary-findings-from-venovalve-health-economic-study-which-indicate-that-the-venovalve-would-be-a-cost-effective-treatment-option-for-patients-with-severe-chronic-venous-insufficiency-caused-by-deep-valvular-incompetency

Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower co...

 envveno-medical-to-present-interim-two-year-follow-up-data-on-42-subjects-from-75-person-venovalve-us-pivotal-trial-at-svs-vam25

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continu...

 envveno-medical-announces-that-its-manuscript-titled-three-year-outcomes-of-surgical-implantation-of-a-novel-bioprosthetic-valve-for-the-treatment-of-deep-venous-reflux-has-been-published-in-the-in-the-peer-reviewed-journal-annals-of-vascular-surgery

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe an...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION